.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
Daiichi Sankyo
US Army
Argus Health
Federal Trade Commission
Julphar
Medtronic
Fuji
McKinsey

Generated: September 19, 2017

DrugPatentWatch Database Preview

Desmopressin acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for desmopressin acetate and what is the scope of desmopressin acetate patent protection?

Desmopressin acetate
is the generic ingredient in ten branded drugs marketed by Apotex Inc, Sun Pharm Inds, Hospira, Ferring Pharms Inc, Impax Labs Inc, Bausch And Lomb, Glenmark Pharms Ltd, Ferring, Sagent Pharms, Mylan Pharms Inc, Serenity Pharms Llc, Actavis Labs Fl Inc, Sun Pharma Global, Bedford, Sun Pharm Inds Ltd, Heritage Pharma, and Teva Pharms Usa, and is included in twenty-five NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Desmopressin acetate has fifty-four patent family members in twenty-eight countries.

There are nineteen drug master file entries for desmopressin acetate. Twenty-five suppliers are listed for this compound.

Summary for Generic Name: desmopressin acetate

Tradenames:10
Patents:4
Applicants:17
NDAs:25
Drug Master File Entries: see list19
Suppliers / Packagers: see list25
Bulk Api Vendors: see list54
Clinical Trials: see list987
Patent Applications: see list5,644
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:desmopressin acetate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)
desmopressin acetate
SPRAY, METERED;NASAL078271-001Dec 23, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
DESMOPRESSIN ACETATE
desmopressin acetate
SPRAY, METERED;NASAL074830-001Jan 25, 1999ABRXNoYes► Subscribe► Subscribe► Subscribe
Bedford
DESMOPRESSIN ACETATE
desmopressin acetate
INJECTABLE;INJECTION074575-001Feb 18, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
DESMOPRESSIN ACETATE
desmopressin acetate
TABLET;ORAL200653-001Jun 27, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds
DESMOPRESSIN ACETATE
desmopressin acetate
SOLUTION;NASAL077212-001Apr 12, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Ferring Pharms Inc
STIMATE (NEEDS NO REFRIGERATION)
desmopressin acetate
SPRAY, METERED;NASAL020355-002Oct 24, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938-002Apr 25, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Serenity Pharms Llc
NOCTIVA
desmopressin acetate
SPRAY, METERED;NASAL201656-002Mar 3, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Ferring
MINIRIN
desmopressin acetate
SPRAY, METERED;NASAL021333-001Sep 16, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
Ferring Pharms Inc
STIMATE
desmopressin acetate
SPRAY, METERED;NASAL020355-001Mar 7, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: desmopressin acetate

Non-Orange Book Patents for Generic Ingredient: desmopressin acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,560,429Orodispersible dosage forms of desmopressin acetate► Subscribe
9,220,747Methods using desmopressin acetate in orodispersible form► Subscribe
8,802,624Methods of treatment using orodispersible desmopressin pharmaceutical formulations► Subscribe
8,143,225Pharmaceutical compositions including low dosages of desmopressin► Subscribe
7,947,654Pharmaceutical formulations► Subscribe
9,504,647Pharmaceutical formulations of desmopressin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: desmopressin acetate

Country Document Number Estimated Expiration
China102647993► Subscribe
Norway335167► Subscribe
Canada2484724► Subscribe
Poland208482► Subscribe
Argentina039794► Subscribe
European Patent Office1501534► Subscribe
Germany60307082► Subscribe
Canada2765221► Subscribe
Israel164519► Subscribe
South Korea20120046176► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Accenture
Cipla
Cerilliant
Mallinckrodt
Dow
Argus Health
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot